Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 29, 2016. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific executive compensation transaction and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific transaction: the exercise of a nil cost option by David Redfern, a Person Discharging Managerial Responsibility.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports the mechanics of a share option exercise under the GlaxoSmithKline Deferred Annual Bonus Plan.
Important Facts for Investors
- Executive Transaction: David Redfern exercised a nil cost option over 10,604 Ordinary Shares on March 29, 2016.
- Share Delivery: The company delivered 5,519 shares representing the net-of-tax value.
- Share Price: The fair market value of an Ordinary Share at the time of exercise was £13.85.
- Plan Details: The option was granted on February 28, 2013, and vested on February 28, 2016.